A new era in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): clinical breakthroughs and challenges.

You Z, Yang L, Long Y, You D, Zhao Q.

Open source

DOI
10.3389/fphar.2026.1815576
Published
2026-08-31
Container
Front Pharmacol
Publisher
Not recorded
Open access
yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fphar.2026.1815576,
  title = {A new era in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): clinical breakthroughs and challenges.},
  author = {You Z and  Yang L and  Long Y and  You D and  Zhao Q.},
  year = {2026},
  journal = {Front Pharmacol},
  doi = {10.3389/fphar.2026.1815576},
  url = {https://doi.org/10.3389/fphar.2026.1815576}
}

RIS

TY  - JOUR
TI  - A new era in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): clinical breakthroughs and challenges.
AU  - You Z
AU  -  Yang L
AU  -  Long Y
AU  -  You D
AU  -  Zhao Q.
PY  - 2026
JO  - Front Pharmacol
DO  - 10.3389/fphar.2026.1815576
UR  - https://doi.org/10.3389/fphar.2026.1815576
ER  - 

APA

Z, Y., L, Y., Y, L., D, Y., & Q., Z. (2026). A new era in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): clinical breakthroughs and challenges.. Front Pharmacol. https://doi.org/10.3389/fphar.2026.1815576

Source records